Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration.
Meliani A, Boisgerault F, Hardet R, Marmier S, Collaud F, Ronzitti G, Leborgne C, Costa Verdera H, Simon Sola M, Charles S, Vignaud A, van Wittenberghe L, Manni G, Christophe O, Fallarino F, Roy C, Michaud A, Ilyinskii P, Kishimoto TK, Mingozzi F.
Meliani A, et al. Among authors: ilyinskii p.
Nat Commun. 2018 Oct 5;9(1):4098. doi: 10.1038/s41467-018-06621-3.
Nat Commun. 2018.
PMID: 30291246
Free PMC article.